EMEA-002377-PIP01-18 - paediatric investigation plan

Elotuzumab

Key facts

• Invented name:
  Empliciti
• Active Substance:
  Elotuzumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0267/2018
• PIP number:
  EMEA-002377-PIP01-18
• Pharmaceutical form(s):
  Powder for concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of Multiple Myeloma
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  13/08/2018

Decision

P/0267/2018: EMA decision of 13 August 2018 on the granting of a product specific waiver for elotuzumab (Empliciti), (EMEA-002377-PIP01-18)

Reference Number: EMA/534276/2018